ClinicalTrials.gg
RecruitingNCT04748640BEST-GKUpdated Nov 17, 2021

Bilateral Essential Tremor Treatment With Gamma Knife

A Phase 2/3 interventional study of Gamma Knife VIM thalamotomy in Essential Tremor, sponsored by Université de Sherbrooke. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-17.

Sponsored by Université de Sherbrooke · Phase 2/3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 26 studies in Essential Tremor with a site in Canada — 8 open to participants now, 11 under way, 1 of them phase 3. Essential Tremor · Canada.

Planned enrollment
6th of 22
50 · median 22
Started
2021
with 3 others
Phase 2/3
Only one
of the 26
Primary completion
2026-02
later than 2 of 10 live
Registered
16th of 26
by date

Among the 26 studies in Essential Tremor with a site in Canada, this one is the 6th largest by planned enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2021, is the only one in phase 2/3, reaches primary completion later than 2 of the 10 other live ones, and was the 16th registered.

Essential Tremor

272 studies on the registry are indexed under Essential Tremor; 75 are open to participants now.

Browse Essential Tremor studies →

Open to participants now

8 of the 26 studies in Essential Tremor with a site in Canada are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 61 Essential Tremor studies recruiting now, 32 (52%) set no upper age limit and 5 (8%) stop at 75 or younger; 8 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies in Essential Tremor with a site in Canada, or all of them as a file.
02

Study summary

Combined Phase II/III, multi-center, prospective, single-blinded trial.

Ten (10) patients with essential tremor who previously underwent successful and uncomplicated GK thalamotomy for essential tremor will undergo a contralateral treatment. The incidence of side effects will be determined at 3 months postoperatively, graded per the CTCAE v5 and analyzed by a data safety monitoring board. Upon successful review, this Phase II trial will be converted to a Phase III trial of utility that will enrol 40 additional patients. The primary outcome will be the change in QUEST score at 12 months postoperatively, as well as a patient-reported assessment of Health Utility. Secondary outcomes will include objective tremor, gait and speech assessments (filmed and scored by blinded evaluators), as well as quality of life questionnaires and adverse events questionnaires. Outcomes will be assessed at baseline, as well as 3, 6, 12, 24 and 36 months post-operatively.

03

Conditions studied

  • Essential Tremor

Keywords

  • Gamma Knife Thalamotomy
  • Tremor
  • Essential Tremor
  • Dyskinesias
  • Neurologic Manifestations
  • Nervous System Diseases
  • Movement Disorders
  • Central Nervous System Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must be ≥ 18 years
  • The patient has a primary diagnosis of ET or ET plus confirmed by a movement disorder neurologist;
  • The patient previously underwent a GK thalamotomy (> 12 months ago);
  • The tremor on the untreated side negatively impacts the patients' quality of life;
  • The patient wants treatment of the contralateral side.

Exclusion criteria

Exclusion Criteria:

  • gait and/or balance impairment (e.g. wide-based, more than 2 falls/months, wheelchair, walker, cane use);
  • Clinically relevant speech impairment (e.g. impairment of intelligibility);
  • Inability to comply with the follow-up schedule;
  • Refusal of the treating physician.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Treatment group

    Participants will undergo a thalamotomy contralateral to their previous treatment with Gamma Knife using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).

    Procedure: Gamma Knife VIM thalamotomy

Interventions

  • ProcedureGamma Knife VIM thalamotomy

    Ablation of contralateral VIM nucleus of thalamus with GK using a frame-based, Gamma Knife Perfexion or Icon unit (Elekta, Stockholm, Sweden).

06

What researchers measure

Primary outcomes

  1. Change in QUEST Score

    Difference in QUEST score between baseline and the 12-month follow-up, with statistical significance defined as p = 0.05 and a minimum clinically important difference (MCID) defined as 5

    Time frame: 12 months

  2. Patient-based Assessment of Utility

    A patient-reported assessment of utility after 12 months using the question "Knowing what you know now, would you do this treatment again?".

    Time frame: 12 months

Secondary outcomes

  1. Gait Assessment (NRS-11)

    Patient-reported and blinded observer rating of the patient's ability to walk (Numerical rating scale (NRS-11) from 0 to 10, with 10 being best)

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  2. Gait Assessment (missteps)

    Number of missteps in a 6 m standardized tandem walk

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  3. Falls

    Number of falls in last month

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  4. Speech Assessment (NRS-11)

    Patient-reported and blinded observer rating of the patient's ability to speak (Numerical rating scale (NRS-11) from 0 to 10, with 10 being best)

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  5. Numbness

    Incidence of new-onset numbness

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  6. Dysgeusia

    Incidence of taste alterations

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  7. Other adverse events

    Incidence of other adverse events as classified in the CTCAE

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  8. Tremor (CRST)

    Assessment of tremor using the Clinical Rating Scale for Tremor (CRST) parts A (0-88) and B (0-36), higher scores correspond to a worse tremor).

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  9. Quality of life (QUEST)

    QUality of life in ESsential Tremor (QUEST) questionnaire (0-100 percent, higher scores correspond to a worse quality of life)

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  10. Quality of life (CRST part C)

    Part C of the Clinical Rating Scale for Tremor (CRST) (0-32, higher scores correspond to a worse quality of life)

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

  11. Health Utility (EQ-5D-5L)

    Health Utility measured using the EQ-5D-5L and computed using the Canadian preference weights. Values range from 0 to 1, with 1 representing a perfect health.

    Time frame: Baseline, post operative month 3, 6, 12, 24, 36

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2021 (actual). Primary completion is estimated for Feb 2026, 56 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2021
First posted
Feb 10, 2021
StartActual
Jun 8, 2021
Primary completionEst.
Feb 2026
CompletionEst.
Oct 2026
Last update
Nov 17, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04748640
Responsible party
Christian Iorio-Morin (Assistant professor of neurosurgery, Université de Sherbrooke) — Principal investigator
First posted
Feb 10, 2021
Start date
Jun 8, 2021
Primary completion
Feb 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Nov 17, 2021

Study contacts

Christian Iorio-Morin
Contact
christian.iorio-morin@usherbrooke.ca
819-346-1110

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion